VJHemOnc is committed to improving our service to you

VJVirtual | Lentiviral vectors and ConvertibleCAR-T therapy

VJHemOnc is committed to improving our service to you

Gurutz Linazasoro

Gurutz Linazasoro, MD, VIVEbiotech, Gipuzkoa, Spain, discusses the manufacturing of lentiviral vectors in supporting the development of ConvertibleCAR-T cell therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics
Related videos
1:53
European regulation and access to advanced therapies
Aurélie Mahalatchimy
5:40
Gene editing: legal and ethical considerations
Aurélie Mahalatchimy
3:02
NK-CAR immunotherapy development over the past 12 months
Evelyn Ullrich
1:17
NK-CAR immunotherapy: the next steps
Evelyn Ullrich
3:06
Safety and outcome of prophylactic high-dose donor CD45RO+ memory T-cells after allo-HSCT
Mercedes Gasior Kabat
General
VJVirtual
Interview
21st July 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals